East Windsor-based Aurex Laboratories was acquired by APNAR Pharma LP for an undisclosed amount, according to a Thursday announcement.
With the addition of Aurex’s manufacturing and research & development capabilities, APNAR plans to transition into a fully integrated global company.
The acquisition enhances California-based APNAR’s scale and global footprint and broadens its pipeline. Not only does it add to APNAR’s commitment of having manufacturing in the U.S., it adds a state-of-the-art facility with the addition of Aurex Laboratories’ 68,000-square-foot site which sits within a 14-acre campus in “the medicine chest” of New Jersey.
It also adds a team of experienced, highly capable and dedicated scientists, manufacturing, regulatory and project management personnel.
“In addition to developing and manufacturing APNAR’s own products, we are looking forward to working in a collaborative manner with other companies for contract and co-development and contract manufacturing,” Dharmesh Patel, president of APNAR, said in a news release.
Nailesh Bhatt acted as a strategic adviser to both Aurex Laboratories and APNAR Pharma.
